Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 51, Issue 1, 2010, Pages 27-38

  Awan, Farrukh T ^a   Johnson, Amy J ^b   Lapalombella, Rosa ^b   Hu, Weihong ^b   Lucas, Margaret ^b   Fischer, Beth ^b   Byrd, John C ^b,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Chronic lymphocytic leukemia; Lenalidomide; Thalidomide; Tumor flare reaction; Tumor lysis syndrome

Indexed keywords

FLUDARABINE; LENALIDOMIDE; OBLIMERSEN; RITUXIMAB; THALIDOMIDE;

ANEMIA; BONE MARROW SUPPRESSION; BRAIN TOXICITY; CANCER SURVIVAL; CELL ACTIVATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE ESCALATION; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; NATURAL KILLER CELL; NEUROPATHY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR FLARE; TUMOR LYSIS SYNDROME; VENOUS THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEDICAL ONCOLOGY; T-LYMPHOCYTES; THALIDOMIDE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 74949135128     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903350405     Document Type: Review

References (66)

1. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25:793-798.
2. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007;370:230-239.
3. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-891.
4. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
5. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49-53.
6. Hallek M, Fingerle-Rowson G, Fink A-M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008; 112(Suppl.):325 (Abstract).
7. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561.
8. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-1364.
9. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003;82:759-765.
10. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
11. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111: 1094-1100.
12. Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196-203.
13. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281.
14. Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005;90: 1435-1436.
15. Thornton PD, Hamblin M, Treleaven JG, Matutes E, Lakhani AK, Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999;34: 167-170.
16. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolonerituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48: 2412-2417.
17. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-2053.
18. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year followup of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912-4920.
19. Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:4389-4396.
20. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96:2917-2924.
21. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006.
22. Castro JE, Prada CE, Aguillon RA, et al. Thymidinephosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 2006;20:680-688.
23. Kay NE, Geyer S, Yaqoob I. Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): a North Central Cancer Treatment Group (NCCTG) study. Blood 2003; 102(Suppl.):5162a (Abstract).
24. Grinblatt DL, Johnson J, Niedzwicki D, Rizzieri DA, Bartlett N, Cheson BD. Phase II study of thalidomide in escalating doses for follicular (F-NHL) and small lymphocytic lymphoma (Sll): CALGB Study 50002. Blood 2004;104(Suppl.): 3284 (Abstract).
25. Kay NE, Shanafelt TD, Call TG, Wu W, Laplant BR. N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2009;50: 588-592.
26. NCI, CETP. Common terminology criteria for adverse events (CTCAE). 3rd ed. NIH; 2006. p 70. http://ctep.cancer.gov/ protocoldevelopment/electronic- applications/docs/ctcaev3notice. pdf, accessed June 30, 2009.
27. Furman RR, Leonard JP, Allen SL, Coleman M, Rosenthal T, Gabrilove JL. Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL. J Clin Oncol 2005; 23(Suppl.):6640 (Abstract).
28. Laurenti L, Piccioni P, Tarnani M, et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res 2007;31:253-256.
29. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatmentrequiring chronic lymphocytic leukemia (CLL). Blood 2005; 106:3348-3352.
30. Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009;23:1771-1778.
31. Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalidomide alone and in combination with fludarabine exerts distinct molecular and antileukemic effects in B-cell chronic lymphocytic leukemia. Blood 2007;110(Suppl.):3124 (Abstract).
32. Furman RR, Allen SL, Leonard JP, Coleman M, Markis JM, Gabrilove JL. Thalidomide is active alone and in combination with fludarabine in fludarabine-relapsed and refractory chronic lymphocytic leukemia. Blood 2004;104(Suppl.):4835 (Abstract).
33. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349.
34. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111: 5291-5297.
35. Wendtner CM, Mahadevan D, Stilgenbauer S, et al. Preliminary results of a phase 1/2, multi-center, open-label study (CLL-001) investigating a stepwise dose-escalation schedule of lenalidomide in relapsed or refractory chronic lymphocytic leukemia. Blood 2008;112(Suppl.):2104 (Abstract).
36. Witzig TE, Vose JM, Kaplan HP, et al. Early results from a phase II study of lenalidomide monotherapy in relapsed/ refractory indolent non-Hodgkin's lymphoma. Blood 2006; 108(Suppl.):2482 (Abstract).
37. Witzig TE, Vose JM, Justice G, et al. Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin's lymphoma. J Clin Oncol 2008;26:abstr 8573.
38. Andritsos L, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-2525.
39. Moutouh-de Parseval LA, Weiss L, DeLap RJ, Knight RD, Zeldis JB. Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047.
40. Chen C, Paul H, Xu W, et al. A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl.):44 (Abstract).
41. Ferrajoli A, O'Brien S, Wierda W, et al. Lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl.):45 (Abstract).
42. Aue G, Njuguna N, Tian X, et al. Lenalidomide induced cytokine release syndrome in chronic lymphocytic leukemia (CLL): clinical and laboratory correlates of immune activation. Blood 2008;112(Suppl.):2099 (Abstract).
43. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297.
44. Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-{a}. J Immunol 1999;163:380-386.
45. Raje N, Anderson KC. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 2002;14:635-640.
46. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004;22:3212-3214.
47. Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314-322.
48. Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130:75-84.
49. LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004;103:1787-1790.
50. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-1232.
51. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008;118:2427-2437.
52. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Lenalidomide repairs suppressed T cell immunological synapse formation in follicular lymphoma. Blood 2008;112(Suppl.):885 (Abstract).
53. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-216.
54. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96: 2943-2950.
55. Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 2007;109:4816-4824.
56. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35.
57. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci USA 2007;104:11406-11411.
58. James DF, Betty MR, Mosadeghi R, Kipps TJ. Lenalidomide abrogates the protective influence of nurse-like cells on primary chronic lymphocytic leukemia cells in vitro. Blood 2007;110(Suppl.):3116 (Abstract).
59. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984-5992.
60. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008;140:36-45.
61. Zhang L-H, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-hodgkin lymphoma cells are associated with increased SPARC expression. Blood 2008;112(Suppl.):2612 (Abstract).
62. Zhang L-H, Schafer P, Muller G, Stirling D, Bartlett JB. Lenalidomide displays direct anti-non-Hodgkin's lymphoma (NHL) cell activity in association with enhanced SPARC expression but independent of its ability to strongly inhibit NHL cell VEGF production in vitro. Blood 2007;110(Suppl.): 3473 (Abstract).
63. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525-4530.
64. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-2525.
65. Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180-5189.
66. Lapalombella R, Gowda A, Joshi T, et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009;144:848-855.